Attenuvax Related Published Studies
Well-designed clinical trials related to Attenuvax (Measles Vaccine)
Antibiotics for preventing complications in children with measles. [2013]
Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine
using new measles and rubella working seeds in healthy children in Taiwan and
Singapore: a phase II, randomized, double-blind trial. [2013]
Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously. [2011.08.01]
Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225. [2011.07]
Persistence of vaccine-induced measles antibody beyond age 12 months: a comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi. [2011.07]
Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. [2011.06.06]
Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. [2011.05.17]
Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. [2011.03]
Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age. [2011.03]
Diphtheria-tetanus-pertussis vaccine administered simultaneously with measles vaccine is associated with increased morbidity and poor growth in girls. A randomised trial from Guinea-Bissau. [2011.01.10]
Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. [2010.11.30]
Intralesional immunotherapy of common warts: successful treatment with mumps, measles and rubella vaccine. [2010.10]
Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months. [2010.08]
Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. [2010.06]
Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. [2010.02.10]
Knowledge synthesis of benefits and adverse effects of measles vaccination: the Lasbela balance sheet. [2009.10.14]
Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. [2009.05.05]
Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. [2009.04.14]
Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. [2008.08]
Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. [2008.07.24]
Antibiotics for preventing complications in children with measles. [2008.07.16]
Sero-response to measles vaccination at 12 months of age in Saudi infants in Qassim Province. [2008.07]
Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. [2008.03]
Antigen-specific lymphocyte proliferation assay and virus neutralization test for measurement of measles-specific immunity in 15-19 years old high school students in Tehran, Iran. [2007.11.15]
Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. [2007.10]
Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. [2007.08]
Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live). [2007.06]
A clinical study to assess the safety and immunogenicity of attenuated measles vaccine administered intranasally to healthy adults. [2007.03]
Associations between measles vaccine immunity and single-nucleotide polymorphisms in cytokine and cytokine receptor genes. [2007.01.01]
Prevalence of antibodies against measles, mumps, and rubella before and after vaccination of school-age children with three different triple combined viral vaccines, Rio Grande do Sul, Brazil, 1996. [2006.11]
Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix or MMR-II. [2006.07.26]
The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. [2006.07]
Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. [2006.04]
Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. [2006.04]
A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. [2006.02]
Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children. [2005.12]
Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. [2005.08]
Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds. [2005.03]
[Cumulative vaccination coverage of measles- and oral polio vaccine obtained by the nationwide survey] [2005.01]
Topical 4% amethocaine gel reduces the pain of subcutaneous measles-mumps-rubella vaccination. [2004.12]
Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. [2004.05.01]
Effect of choice of measles-mumps-rubella vaccine on immediate vaccination pain in infants. [2004.04]
Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old. [2004.03]
Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity. [2004.03]
Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. [2004.01.15]
Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months. [2003.09]
Survival of previously measles-vaccinated and measles-unvaccinated children in an emergency situation: an unplanned study. [2003.09]
Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. [2003.06.28]
Effect of Vitamin A supplementation on the immune response to measles vaccination. [2003.06.02]
Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. [2002.12.13]
An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. [2002.10]
A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children. [2002.09]
A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. [2002.06.21]
Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. [2002.06]
No evidence for short or long term morbidity after increased titer measles vaccination in Sudan. [2002.02]
Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. [2002]
Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. [2001.08.14]
Serological and epidemiological effects and influence factors of primary immunization with current live attenuated measles vaccine (Hu191) among infants aged 6-15 months. [2001.02.28]
Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine. [2001.02.28]
Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines. [2001]
Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age. [2001]
Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. [2000.11]
Reactogenicity and immunogenicity of a new measles-mumps-rubella vaccine containing RIT 4385 mumps virus strain in healthy Turkish children. [2000.10]
Clinical immunogenicity of measles, mumps and rubella vaccine delivered by the Injex jet injector: comparison with standard syringe injection. [2000.09]
[Seroconversion study of Biken CAM-70 measles vaccine formulations] [2000.08]
Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines. [2000.06.15]
Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response. [2000.06]
Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. [2000.03.04]
Targeted mailing of information to improve uptake of measles, mumps, and rubella vaccine: a randomised controlled trial. [2000.03]
Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. [2000.01.31]
A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age. [1999.09]
Vitamin A administered with measles vaccine to nine-month-old infants does not reduce vaccine immunogenicity. [1999.08]
Early two-dose measles vaccination schedule in Guinea-Bissau: good protection and coverage in infancy. [1999.04]
Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. [1999.03.05]
Mild illness at or after measles vaccination does not reduce seroresponse in young children. [1999.02.26]
Seroconversions in unvaccinated infants: further evidence for subclinical measles from vaccine trials in Niakhar, Senegal. [1999.02]
Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. [1999.01]
Increased long term mortality associated with rash after early measles vaccination in rural Senegal. [1999.01]
Immunogenicity and safety of standard-titer AIK-C measles vaccine in nine-month-old infants. [1999]
Randomised controlled trial of the use of a modified postal reminder card on the uptake of measles vaccination. [1998.08]
Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children. [1998.07]
Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. [1998.01]
Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana. [1998]
Measles incidence, case fatality, and delayed mortality in children with or without vitamin A supplementation in rural Ghana. [1997.10.15]
Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa. [1997.07.12]
Enhancement in seroconversion to measles vaccine with simultaneous administration of vitamin A in 9-months-old Indian infants. [1997.07]
Effect of vitamin A supplementation on measles vaccination in nine-month-old infants. [1997.07]
Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group. [1997.07]
Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group. [1997.05]
Measles vaccine in egg allergic children: poor immunogenicity of the Edmoston-Zagreb strain. [1997.02]
Field trial of combined yellow fever and measles vaccines among children in Nigeria. [1996.09]
Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children. [1996.03]
Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. [1995.06]
Reduced seroconversion to measles in infants given vitamin A with measles vaccination. [1995.05.27]
Comparison of Edmonston-Zagreb, Connaught and Schwarz measles vaccines in Cameroonian infants aged 3-8 months. [1995.02]
Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. [1994.10]
Immunization of 6 and 9 month old infants with AIK-C, Edmonston-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine. [1994.10]
Intradermal administration of measles vaccines. [1994.09]
Trials of Edmonston-Zagreb measles vaccine in Guinea-Bissau: serological responses following vaccination with Edmonston-Zagreb strain at 4-8 months versus vaccination with Schwarz strain at 9-12 months of age. [1994.08]
Adolescent measles vaccination. Response rates to mailings addressed to patients vs parents. [1994.07]
Long-term survival in trial of medium-titre Edmonston-Zagreb measles vaccine in Guinea-Bissau: five-year follow-up. [1994.04]
|